Merck (NYSE:MRK) Stock Upgrade
Barclays raised shares of Merck (NYSE:MRK) stock to a Overweight rating from their previous Equal Weight. The announcement of this change was revealed in recent note earlier today. The firm presently has a respectable $66 target on shares. –
From a total of 18 analysts covering Merck & Co. Inc. (NYSE:MRK) stock, 8 rate it a ”Buy”, 0 a “Sell”, and 11 a ”Hold”. This means that 42% of the ratings are positive. The highest target price is $72 while the lowest target price is $54. The mean of all analyst targets is $62.56 with a 18.79% above today’s ($54.02) stock price. Merck & Co. Inc. was the topic of 11 analyst reports since August 13, 2015 according to the firm StockzIntelligence Inc. Barclays Capital upgraded shares on December 1 to “Overweight” rating. BMO Capital Markets upgraded shares to “Outperform” rating and $70 target share price in a report from an August 13. Argus Research maintained MRK stock in a recent report from November 17 with “Buy” rating. Finally, JP Morgan maintained the stock with “Overweight” rating in a report issued on a September 21.
Approximately 6.33M shares of stock traded hands. Merck & Co., Inc. (NYSE:MRK) has declined 11.62% since April 28, 2015 and is downtrending. It has underperformed by 10.00% the S&P500.
Merck & Co., Inc. is a global health care company. The company has a market cap of $153.44 billion. The Firm offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It has 14.4 P/E ratio. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
According to Zacks Investment Research, “Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.” Get a free copy of the Zacks research report on Merck & Co., Inc. (MRK)